AFT PHARMACEUTICALS
AFT
 End-of-day quote - 04/16 |
|
| 4.1NZD | -1.68% |
Business Summary
| Healthcare | ||||
 | Pharmaceuticals & Medical Research | |||
| Pharmaceuticals | |||
| Pharmaceuticals | |||
| Other Pharmaceuticals | |||
AFT Pharmaceuticals Limited is a pharmaceutical distributor and developer of pharmaceutical intellectual property. The Company's segments include New Zealand, Australia, Asia and Rest of World. The Company's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The Company's NasoSURF Nebuliser is in pilot scale production. The Company is focused on conducting clinical for Maxigesic oral dose forms. The Company is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.
Sales per Business
| 2019 | 2020 | |||
| NZD (in Million) | % | NZD (in Million) | % | |
| Pharmaceutical | 83.65 | 98.3% | 101.42 | 96% |
| Licensing | 1.22 | 1.4% | 3.83 | 3.6% |
| Royalties | 0.255 | 0.3% | 0.356 | 0.3% |
Sales per region
| 2019 | 2020 | |||
| NZD (in Million) | % | NZD (in Million) | % | |
| Australia | 50.30 | 59.1% | 61.43 | 58.2% |
| New Zealand | 26.80 | 31.5% | 30.11 | 28.5% |
| Rest of World | 5.89 | 6.9% | 9.13 | 8.6% |
| Southeast Asia | 2.14 | 2.5% | 4.93 | 4.7% |
Managers
| Name | Title |
| Hartley Atkinson | Chief Executive Officer, MD & Executive Director |
| Malcolm Tubby | Chief Financial Officer & Secretary |
| David Mark Flacks | Chairman |
| Douglas John Wilson | Independent Non-Executive Director |
| Jon Lamb | Independent Non-Executive Director |
| James S. Burns | Independent Non-Executive Director |
| Anita Baldauf | Independent Non-Executive Director |
| Marree Atkinson | Executive Director & Chief of Staff |
| Theodore J. Witek | Director |
| Murray Keith | Marketing Manager |
| Shareholders |
| Name | Equities | % |
| Norges Bank Investment Management | 2,208,153 | 2.11% |
| Hartley Atkinson | 1,617,818 | 1.55% |
| Accident Compensation Corp. | 852,002 | 0.81% |
| Guardians of New Zealand Superannuation | 737,134 | 0.70% |
| Jon Lamb | 248,094 | 0.24% |
| Joeri Yvonne Jozef Sels | 220,642 | 0.21% |
| Hamish Atkinson | 190,000 | 0.18% |
| David Mark Flacks | 178,764 | 0.17% |
| Joseph Wallace Carson | 150,000 | 0.14% |
| James S. Burns | 125,417 | 0.12% |
Company contact information
AFT Pharmaceuticals Ltd.
Nielsen House
129 Hurstmere Road, Takapuna
Level 1
Auckland 0622
Phone : +64.800.423.823
Fax : +64.800.423.874
Web : http://www.aftpharm.com
Nielsen House
129 Hurstmere Road, Takapuna
Level 1
Auckland 0622
Phone : +64.800.423.823
Fax : +64.800.423.874
Web : http://www.aftpharm.com
Sector Other Pharmaceuticals
| 1st jan. | Capi. (M$) | ||
 | |||
| AFT PHARMACEUTICALS LIMITED | -25.59% | 306 | |
| |||
| JOHNSON & JOHNSON | 3.09% | 427 130 | |
| ROCHE HOLDING AG | 0.16% | 289 376 | |
| PFIZER INC. | 2.15% | 215 150 | |
| NOVARTIS AG | -3.73% | 198 528 | |
| MERCK & CO., INC. | -5.29% | 196 100 | |
| ABBVIE INC. | 0.71% | 190 442 | |
| ELI LILLY AND COMPANY | 12.09% | 172 027 | |
| NOVO NORDISK A/S | 4.65% | 166 925 | |
| AMGEN INC. | 10.96% | 147 238 | |
| BRISTOL-MYERS SQUIBB COMPANY | 3.89% | 146 233 | |
| ASTRAZENECA PLC | 0.76% | 133 897 | |
| SANOFI | 8.02% | 127 185 | |
| GLAXOSMITHKLINE PLC | 0.33% | 92 715 | |
| JIANGSU HENGRUI MEDICINE CO., LTD. | -27.67% | 65 639 | |
| CHUGAI PHARMACEUTICAL CO., LTD. | -21.50% | 65 254 | |
| ALLERGAN PLC | 0.97% | 63 659 | |
| BAYER AG | 12.14% | 63 549 | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | -1.36% | 53 250 | |
| DAIICHI SANKYO COMPANY, LIMITED | -14.99% | 52 906 | |
| ASTELLAS PHARMA INC. | 3.39% | 28 128 | |
